UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Starting your investment journey? Learn what to watch out for as a new investor to avoid common pitfalls and make wise choices.
27,695 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Tilray Brands is targeting a milestone $1.2 billion in annual revenue next year. This article digs into how the compa...
A focused look at OmniAb's Q4 2025 earnings and what the numbers could mean for investors. Discover the drivers, risk...
SpaceX may steal headlines, but the real action for investors is in the earnings reports of BlackSky, Redwire, and Ro...
A recent SEC filing shows Marshall Investment Management adding a sizable stake to the TCW Flexible Income ETF (FLXR)...
As Cerebras moves toward its IPO, investors grapple with hype and reality. This guide breaks down what cerebras ipo: ...
Kevin Warsh chairs his first FOMC meeting as crypto markets brace for policy clarity. Bitcoin steadies near 66,000 wh...
Bitcoin prices have fallen from their peak while on-chain activity climbs. This article breaks down what rising activ...
Oracle’s $523 billion backlog raises timing concerns as capex surges. cnbc’s deirdre bosa warns that the chip upgrade...
Quantum tech is finally moving from labs to portfolios. This article breaks down why d-wave quantum shares soaring ha...
A public clash between a legendary director and a veteran actor isn’t just drama. It’s a window into how money, reput...
The shift in AI spending is reshaping winners and losers. This article explains why a power-semiconductor-focused com...